ImmuPharma PLC
Status: Publicly traded
Direct answer
ImmuPharma PLC is publicly traded on LSE under the ticker IMM.L.
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom. Its peptide-based therapeutics focuses on autoimmunity and inflammation, and anti-infectives therapeutic areas. The company’s lead product candidate includes P140, a peptide technology platform, which is in Phase III clinical trial that targets autoimmune diseases for systemic lupus erythematosus;...
Can you invest in ImmuPharma PLC?
Yes. ImmuPharma PLC trades publicly on LSE as IMM.L.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for ImmuPharma PLC
Detailed equity research is provided by MarketSnap.